Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67492
Full metadata record
???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
---|---|---|
dc.contributor.advisor | 劉俊人 | |
dc.contributor.author | Yung-Tsung Li | en |
dc.contributor.author | 李泳璁 | zh_TW |
dc.date.accessioned | 2021-06-17T01:34:35Z | - |
dc.date.available | 2022-09-12 | |
dc.date.copyright | 2017-09-12 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-02 | |
dc.identifier.citation | Aasland, R., Stewart, A. F. and Gibson, T. 'The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB.' Trends Biochem Sci 1996 Mar; 21(3): 87-88. Anji, A. and Kumari, M. 'Guardian of Genetic Messenger-RNA-Binding Proteins.' Biomolecules 2016 6(1): 4. Aramaki, Y., Ogawa, K., Toh, Y., Ito, T., Akimitsu, N., Hamamoto, H., Sekimizu, K., Matsusue, K., Kono, A., Iguchi, H. and Takiguchi, S. 'Direct interaction between metastasis-associated protein 1 and endophilin 3.' FEBS Lett 2005 Jul 04; 579(17): 3731-3736. Bagheri-Yarmand, R., Balasenthil, S., Gururaj, A. E., Talukder, A. H., Wang, Y. H., Lee, J. H., Kim, Y. S., Zhang, X., Jones, D. M., Medeiros, L. J., Stephens, L. C., Liu, Y. J., Lee, N., Kim, I. and Kumar, R. 'Metastasis-associated protein 1 transgenic mice: a new model of spontaneous B-cell lymphomas.' Cancer Res 2007 Aug 01; 67(15): 7062-7067. Beasley, R. P., Hwang, L. Y., Lin, C. C. and Chien, C. S. 'Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.' Lancet 1981 Nov 21; 2(8256): 1129-1133. Boender, P. J., Schalm, S. W. and Heijtink, R. A. 'Detection of integration during active replication of hepatitis B virus in the liver.' J Med Virol 1985 May; 16(1): 47-54. Brechot, C. 'Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.' Gastroenterology 2004 Nov; 127(5 Suppl 1): S56-61. Brewer, G. 'An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro.' Mol Cell Biol 1991 May; 11(5): 2460-2466. Brown, R. S. 'Zinc finger proteins: getting a grip on RNA.' Curr Opin Struct Biol 2005 Feb; 15(1): 94-98. Bruix, J., Sherman, M. and Practice Guidelines Committee, A. A. f. t. S. o. L. D. 'Management of hepatocellular carcinoma.' Hepatology 2005 Nov; 42(5): 1208-1236. Buchan, D. W., Minneci, F., Nugent, T. C., Bryson, K. and Jones, D. T. 'Scalable web services for the PSIPRED Protein Analysis Workbench.' Nucleic Acids Res 2013 Jul; 41(Web Server issue): W349-357. Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, D. R., Martin, E., Murad, F. and Kumar, R. 'Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator.' J Biol Chem 2010 Mar 5; 285(10): 6980-6986. Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, R. D., Xia, W., Hung, M. C., Sarin, S. K., Kumar, V., Slagle, B. L. and Kumar, R. 'NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx.' Oncogene 2010 Feb 25; 29(8): 1179-1189. Buurman, R., Gurlevik, E., Schaffer, V., Eilers, M., Sandbothe, M., Kreipe, H., Wilkens, L., Schlegelberger, B., Kuhnel, F. and Skawran, B. 'Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.' Gastroenterology 2012 Sep; 143(3): 811-820 e811-815. Callebaut, I., Courvalin, J. C. and Mornon, J. P. 'The BAH (bromo-adjacent homology) domain: a link between DNA methylation, replication and transcriptional regulation.' FEBS Lett 1999 Mar 05; 446(1): 189-193. Chang, M. H. C., D.S. (2009). HEPATITIS B VACCINE AND HEPATOCELLULAR CARCINOMA Wiley-Blackwell. Chen, C. J., Wang, L. Y. and Yu, M. W. 'Epidemiology of hepatitis B virus infection in the Asia-Pacific region.' J Gastroenterol Hepatol 2000 May; 15 Suppl: E3-6. Chen, C. J., Yang, H. I., Su, J., Jen, C. L., You, S. L., Lu, S. N., Huang, G. T., Iloeje, U. H. and Group, R.-H. S. 'Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.' JAMA 2006 Jan 04; 295(1): 65-73. Chen, M. F., Hwang, T. L., Jeng, L. B., Wang, C. S., Jan, Y. Y. and Chen, S. C. 'Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years.' Arch Surg 1994 Jul; 129(7): 738-742. Chen, Y. J., Yeh, S. H., Chen, J. T., Wu, C. C., Hsu, M. T., Tsai, S. F., Chen, P. J. and Lin, C. H. 'Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma.' Gastroenterology 2000 Aug; 119(2): 431-440. Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T. S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W. Y., Pan, H., Burock, K., Zou, J., Voliotis, D. and Guan, Z. 'Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.' Lancet Oncol 2009 Jan; 10(1): 25-34. Cléry, A. and Allain, F. H. (2012). From structure to function of RNA binding domains. Austin, Tex., Landes Bioscience. Deng, L., Yang, H., Tang, J., Lin, Z., Yin, A., Gao, Y., Wang, X., Jiang, R. and Sun, B. 'Inhibition of MTA1 by ERalpha contributes to protection hepatocellular carcinoma from tumor proliferation and metastasis.' J Exp Clin Cancer Res 2015 Oct 26; 34: 128. Dhar, S., Kumar, A., Li, K., Tzivion, G. and Levenson, A. S. 'Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer.' Biochim Biophys Acta 2015 Feb; 1853(2): 265-275. Dhar, S., Kumar, A., Zhang, L., Rimando, A. M., Lage, J. M., Lewin, J. R., Atfi, A., Zhang, X. and Levenson, A. S. 'Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer.' Oncotarget 2016 Apr 05; 7(14): 18469-18484. Di Bisceglie, A. M. 'Hepatitis B and hepatocellular carcinoma.' Hepatology 2009 May; 49(5 Suppl): S56-60. Dias, S. J., Zhou, X., Ivanovic, M., Gailey, M. P., Dhar, S., Zhang, L., He, Z., Penman, A. D., Vijayakumar, S. and Levenson, A. S. 'Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans.' Sci Rep 2013 3: 2331. Ding, Z., Gillespie, L. L. and Paterno, G. D. 'Human MI-ER1 alpha and beta function as transcriptional repressors by recruitment of histone deacetylase 1 to their conserved ELM2 domain.' Mol Cell Biol 2003 Jan; 23(1): 250-258. Doyle, G. A., Betz, N. A., Leeds, P. F., Fleisig, A. J., Prokipcak, R. D. and Ross, J. 'The c-myc coding region determinant-binding protein: a member of a family of KH domain RNA-binding proteins.' Nucleic Acids Res 1998 Nov 15; 26(22): 5036-5044. el-Serag, H. B. 'Epidemiology of hepatocellular carcinoma.' Clin Liver Dis 2001 Feb; 5(1): 87-107, vi. El-Serag, H. B. 'Hepatocellular carcinoma.' N Engl J Med 2011 Sep 22; 365(12): 1118-1127. El-Serag, H. B. 'Epidemiology of viral hepatitis and hepatocellular carcinoma.' Gastroenterology 2012 May; 142(6): 1264-1273 e1261. El-Serag, H. B. and Rudolph, K. L. 'Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.' Gastroenterology 2007 Jun; 132(7): 2557-2576. Fletcher, S. P., Chin, D. J., Ji, Y., Iniguez, A. L., Taillon, B., Swinney, D. C., Ravindran, P., Cheng, D. T., Bitter, H., Lopatin, U., Ma, H., Klumpp, K. and Menne, S. 'Transcriptomic analysis of the woodchuck model of chronic hepatitis B.' Hepatology 2012 Sep; 56(3): 820-830. Gomaa, A. I., Khan, S. A., Toledano, M. B., Waked, I. and Taylor-Robinson, S. D. 'Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.' World J Gastroenterol 2008 Jul 21; 14(27): 4300-4308. Gu, W., Pan, F. and Singer, R. H. 'Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells.' J Cell Sci 2009 Jun 01; 122(Pt 11): 1895-1905. Gu, W., Wells, A. L., Pan, F. and Singer, R. H. 'Feedback regulation between zipcode binding protein 1 and beta-catenin mRNAs in breast cancer cells.' Mol Cell Biol 2008 Aug; 28(16): 4963-4974. Guan, R. and Lui, H. F. 'Treatment of hepatitis B in decompensated liver cirrhosis.' Int J Hepatol 2011 2011: 918017. Gutschner, T., Hammerle, M., Pazaitis, N., Bley, N., Fiskin, E., Uckelmann, H., Heim, A., Grobeta, M., Hofmann, N., Geffers, R., Skawran, B., Longerich, T., Breuhahn, K., Schirmacher, P., Muhleck, B., Huttelmaier, S. and Diederichs, S. 'Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma.' Hepatology 2014 May; 59(5): 1900-1911. Hamatsu, T., Rikimaru, T., Yamashita, Y., Aishima, S., Tanaka, S., Shirabe, K., Shimada, M., Toh, Y. and Sugimachi, K. 'The role of MTA1 gene expression in human hepatocellular carcinoma.' Oncol Rep 2003 May-Jun; 10(3): 599-604. Hannafon. B.N.; Gaskill, K. C., C.; Ding, W.Q. 'The Role of Metastasis-Associated Protein 1 (MTA1) in Breast Cancer Exosome-Mediated Intercellular Communication.' FASEB J 2017 31(178). Hansen, L. J., Tennant, B. C., Seeger, C. and Ganem, D. 'Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B viruses.' Mol Cell Biol 1993 Jan; 13(1): 659-667. Hartl, M. 'The Quest for Targets Executing MYC-Dependent Cell Transformation.' Front Oncol 2016 6: 132. Henikoff, S. and Henikoff, J. G. 'Automated assembly of protein blocks for database searching.' Nucleic Acids Res 1991 Dec 11; 19(23): 6565-6572. Herrick, D. J. and Ross, J. 'The half-life of c-myc mRNA in growing and serum-stimulated cells: influence of the coding and 3' untranslated regions and role of ribosome translocation.' Mol Cell Biol 1994 Mar; 14(3): 2119-2128. Herszenyi, L. and Tulassay, Z. 'Epidemiology of gastrointestinal and liver tumors.' Eur Rev Med Pharmacol Sci 2010 Apr; 14(4): 249-258. Hung, S. C., Wu, I. H., Hsue, S. S., Liao, C. H., Wang, H. C., Chuang, P. H., Sung, S. Y. and Hsieh, C. L. 'Targeting l1 cell adhesion molecule using lentivirus-mediated short hairpin RNA interference reverses aggressiveness of oral squamous cell carcinoma.' Mol Pharm 2010 Dec 6; 7(6): 2312-2323. Inagawa, S., Itabashi, M., Adachi, S., Kawamoto, T., Hori, M., Shimazaki, J., Yoshimi, F. and Fukao, K. 'Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival.' Clin Cancer Res 2002 Feb; 8(2): 450-456. Jin, Y. J., Chung, Y. H., Kim, J. A., Park, W. H., Lee, D., Seo, D. D., Ryu, S. H., Jang, M. K., Yu, E. and Lee, Y. J. 'Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma.' Dig Dis Sci 2012 Nov; 57(11): 2917-2923. Jones, D. T. 'Protein secondary structure prediction based on position-specific scoring matrices.' J Mol Biol 1999 Sep 17; 292(2): 195-202. Jwo, S. C., Chiu, J. H., Chau, G. Y., Loong, C. C. and Lui, W. Y. 'Risk factors linked to tumor recurrence of human hepatocellular carcinoma after hepatic resection.' Hepatology 1992 Dec; 16(6): 1367-1371. Kang, M. H., Jeong, K. J., Kim, W. Y., Lee, H. J., Gong, G., Suh, N., Gyorffy, B., Kim, S., Jeong, S. Y., Mills, G. B. and Park, Y. Y. 'Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.' Oncogene 2017 Mar 23; 36(12): 1745-1752. Kao, J. H. 'Role of viral factors in the natural course and therapy of chronic hepatitis B.' Hepatol Int 2007 Dec; 1(4): 415-430. Kao, J. H., Chen, P. J., Lai, M. Y. and Chen, D. S. 'Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B.' Gastroenterology 2000 Mar; 118(3): 554-559. Kao, J. H., Chen, P. J., Lai, M. Y. and Chen, D. S. 'Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus.' Hepatology 2001 Oct; 34(4 Pt 1): 817-823. Kawate, S., Fukusato, T., Ohwada, S., Watanuki, A. and Morishita, Y. 'Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression.' Oncology 1999 57(2): 157-163. Kekule, A. S., Lauer, U., Weiss, L., Luber, B. and Hofschneider, P. H. 'Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway.' Nature 1993 Feb 25; 361(6414): 742-745. Kleene, R., Classen, B., Zdzieblo, J. and Schrader, M. 'SH3 binding sites of ZG29p mediate an interaction with amylase and are involved in condensation-sorting in the exocrine rat pancreas.' Biochemistry 2000 Aug 15; 39(32): 9893-9900. Kleene, R., Zdzieblo, J., Wege, K. and Kern, H. F. 'A novel zymogen granule protein (ZG29p) and the nuclear protein MTA1p are differentially expressed by alternative transcription initiation in pancreatic acinar cells of the rat.' J Cell Sci 1999 Aug; 112 ( Pt 15): 2539-2548. Kumar, M., Gromiha, M. M. and Raghava, G. P. 'SVM based prediction of RNA-binding proteins using binding residues and evolutionary information.' J Mol Recognit 2011 Mar-Apr; 24(2): 303-313. Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z., Bagheri-Yarmand, R., Sahin, A., Hortobagyi, G., Adam, L., Barnes, C. J. and Vadlamudi, R. K. 'A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm.' Nature 2002 Aug 8; 418(6898): 654-657. Kwon, S. K., Yun, S. S., Kim, H. J. and Lee, D. S. 'The risk factors of early recurrence after hepatectomy in hepatocellular carcinoma.' Ann Surg Treat Res 2014 Jun; 86(6): 283-288. Lang, H., Sotiropoulos, G. C., Brokalaki, E. I., Schmitz, K. J., Bertona, C., Meyer, G., Frilling, A., Paul, A., Malago, M. and Broelsch, C. E. 'Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers.' J Am Coll Surg 2007 Jul; 205(1): 27-36. Li, D. Q., Divijendra Natha Reddy, S., Pakala, S. B., Wu, X., Zhang, Y., Rayala, S. K. and Kumar, R. 'MTA1 coregulator regulates p53 stability and function.' J Biol Chem 2009 Dec 11; 284(50): 34545-34552. Li, D. Q. and Kumar, R. 'Unravelling the Complexity and Functions of MTA Coregulators in Human Cancer.' Adv Cancer Res 2015 127: 1-47. Li, D. Q., Pakala, S. B., Nair, S. S., Eswaran, J. and Kumar, R. 'Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer.' Cancer Res 2012 Jan 15; 72(2): 387-394. Li, K., Dias, S. J., Rimando, A. M., Dhar, S., Mizuno, C. S., Penman, A. D., Lewin, J. R. and Levenson, A. S. 'Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer.' PLoS One 2013 8(3): e57542. Li, W., Miao, X., Qi, Z., Zeng, W., Liang, J. and Liang, Z. 'Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2.' Virol J 2010 Feb 20; 7: 45. Li, Y. T., Liu, C. J., Su, T. H., Cheng, H. R., Jeng, Y. M., Lin, H. L., Wang, C. C., Kao, J. H., Chen, P. J., Chen, D. S. and Wu, H. L. 'Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-kappaB signaling and tumor progression in a woodchuck hepatocellular carcinoma model.' Oncotarget 2016 Jul 26; 7(30): 47173-47185. Liaw, Y. F. 'Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.' Liver Int 2009 Jan; 29 Suppl 1: 100-107. Liaw, Y. F., Tai, D. I., Chu, C. M., Lin, D. Y., Sheen, I. S., Chen, T. J. and Pao, C. C. 'Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study.' Gastroenterology 1986 Feb; 90(2): 263-267. Lin, C. L. and Kao, J. H. 'Risk stratification for hepatitis B virus related hepatocellular carcinoma.' J Gastroenterol Hepatol 2013 Jan; 28(1): 10-17. Liu, C. J., Chen, B. F., Chen, P. J., Lai, M. Y., Huang, W. L., Kao, J. H. and Chen, D. S. 'Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers.' J Infect Dis 2006 May 01; 193(9): 1258-1265. Liu, C. J. and Kao, J. H. 'Hepatitis B virus-related hepatocellular carcinoma: epidemiology and pathogenic role of viral factors.' J Chin Med Assoc 2007 Apr; 70(4): 141-145. Liu, J., Xu, D., Wang, H., Zhang, Y., Chang, Y., Zhang, J., Wang, J., Li, C., Liu, H., Zhao, M., Lin, C., Zhan, Q., Huang, C. and Qian, H. 'The subcellular distribution and function of MTA1 in cancer differentiation.' Oncotarget 2014 Jul 15; 5(13): 5153-5164. Liu, S., Koh, S. S. and Lee, C. G. 'Hepatitis B Virus X Protein and Hepatocarcinogenesis.' Int J Mol Sci 2016 Jun 14; 17(6). Llovet, J. M., Burroughs, A. and Bruix, J. 'Hepatocellular carcinoma.' Lancet 2003 Dec 06; 362(9399): 1907-1917. Ma, K., Fan, Y., Dong, X., Dong, D., Guo, Y., Wei, X., Ning, J., Geng, Q., Wang, C., Hu, Y., Li, M., Niu, W., Li, E. and Wu, Y. 'MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer.' Oncotarget 2017 Mar 21. Makuuchi, M., Donadon, M. and Torzilli, G. 'Hepatic resection for hepatocellular carcinoma in cirrhosis.' Ann Ital Chir 2008 Mar-Apr; 79(2): 111-115. Maluccio, M. and Covey, A. 'Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma.' CA Cancer J Clin 2012 Nov-Dec; 62(6): 394-399. Manavathi, B. and Kumar, R. 'Metastasis tumor antigens, an emerging family of multifaceted master coregulators.' J Biol Chem 2007 Jan 19; 282(3): 1529-1533. Manavathi, B., Singh, K. and Kumar, R. 'MTA family of coregulators in nuclear receptor biology and pathology.' Nucl Recept Signal 2007 Nov 30; 5: e010. Marrero, J. A., Kudo, M. and Bronowicki, J. P. 'The challenge of prognosis and staging for hepatocellular carcinoma.' Oncologist 2010 15 Suppl 4: 23-33. Matsumata, T., Kanematsu, T., Shirabe, K., Sonoda, T., Furuta, T. and Sugimachi, K. 'Decreased morbidity and mortality rates in surgical patients with hepatocellular carcinoma.' Br J Surg 1990 Jun; 77(6): 677-680. Meier, V. and Ramadori, G. 'Clinical staging of hepatocellular carcinoma.' Dig Dis 2009 27(2): 131-141. Meyer, M., Caselmann, W. H., Schluter, V., Schreck, R., Hofschneider, P. H. and Baeuerle, P. A. 'Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization.' EMBO J 1992 Aug; 11(8): 2991-3001. Michielsen, P. P., Francque, S. M. and van Dongen, J. L. 'Viral hepatitis and hepatocellular carcinoma.' World J Surg Oncol 2005 May 20; 3: 27. Millard, C. J., Fairall, L. and Schwabe, J. W. 'Towards an understanding of the structure and function of MTA1.' Cancer Metastasis Rev 2014 Dec; 33(4): 857-867. Mishra, S. K., Yang, Z., Mazumdar, A., Talukder, A. H., Larose, L. and Kumar, R. 'Metastatic tumor antigen 1 short form (MTA1s) associates with casein kinase I-gamma2, an estrogen-responsive kinase.' Oncogene 2004 May 27; 23(25): 4422-4429. Moeini, A., Cornella, H. and Villanueva, A. 'Emerging signaling pathways in hepatocellular carcinoma.' Liver Cancer 2012 Sep; 1(2): 83-93. Moon, W. S., Chang, K. and Tarnawski, A. S. 'Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: Relationship to vascular invasion and estrogen receptor-alpha.' Hum Pathol 2004 Apr; 35(4): 424-429. Nagaraj, S. R., Shilpa, P., Rachaiah, K. and Salimath, B. P. 'Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma.' Mol Carcinog 2015 May; 54(5): 333-350. Nawa, A., Nishimori, K., Lin, P., Maki, Y., Moue, K., Sawada, H., Toh, Y., Fumitaka, K. and Nicolson, G. L. 'Tumor metastasis-associated human MTA1 gene: its deduced protein sequence, localization, and association with breast cancer cell proliferation using antisense phosphorothioate oligonucleotides.' J Cell Biochem 2000 Aug 02; 79(2): 202-212. Neuveut, C., Wei, Y. and Buendia, M. A. 'Mechanisms of HBV-related hepatocarcinogenesis.' J Hepatol 2010 Apr; 52(4): 594-604. Ng, S. A. and Lee, C. 'Hepatitis B virus X gene and hepatocarcinogenesis.' J Gastroenterol 2011 Aug; 46(8): 974-990. Nguyen, D. H., Ludgate, L. and Hu, J. 'Hepatitis B virus-cell interactions and pathogenesis.' J Cell Physiol 2008 Aug; 216(2): 289-294. Nicolson, G. L., Nawa, A., Toh, Y., Taniguchi, S., Nishimori, K. and Moustafa, A. 'Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation.' Clin Exp Metastasis 2003 20(1): 19-24. Niranjanakumari, S., Lasda, E., Brazas, R. and Garcia-Blanco, M. A. 'Reversible cross-linking combined with immunoprecipitation to study RNA-protein interactions in vivo.' Methods 2002 Feb; 26(2): 182-190. Nordgard, O., Andersen, T. O. and Gabrielsen, O. S. 'Selective inhibition of c-Myb DNA-binding by RNA polymers.' BMC Biochem 2004 Nov 04; 5: 15. Okada, S., Shimada, K., Yamamoto, J., Takayama, T., Kosuge, T., Yamasaki, S., Sakamoto, M. and Hirohashi, S. 'Predictive factors for postoperative recurrence of hepatocellular carcinoma.' Gastroenterology 1994 Jun; 106(6): 1618-1624. Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., Behringer, R. R. and Kumar, R. 'Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis.' J Biol Chem 2010 Jul 30; 285(31): 23590-23597. Park, N. H., Song, I. H. and Chung, Y. H. 'Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.' Gut Liver 2007 Dec; 1(2): 101-117. Parkin, D. M., Stjernsward, J. and Muir, C. S. 'Estimates of the worldwide frequency of twelve major cancers.' Bull World Health Organ 1984 62(2): 163-182. Pons, F., Varela, M. and Llovet, J. M. 'Staging systems in hepatocellular carcinoma.' HPB (Oxford) 2005 7(1): 35-41. Qian, H., Lu, N., Xue, L., Liang, X., Zhang, X., Fu, M., Xie, Y., Zhan, Q., Liu, Z. and Lin, C. 'Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line.' Clin Exp Metastasis 2005 22(8): 653-662. Qian, H., Yu, J., Li, Y., Wang, H., Song, C., Zhang, X., Liang, X., Fu, M. and Lin, C. 'RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model.' Biol Cell 2007 Oct; 99(10): 573-581. Roche, A. E., Bassett, B. J., Samant, S. A., Hong, W., Blobel, G. A. and Svensson, E. C. 'The zinc finger and C-terminal domains of MTA proteins are required for FOG-2-mediated transcriptional repression via the NuRD complex.' J Mol Cell Cardiol 2008 Feb; 44(2): 352-360. Ryu, S. H., Chung, Y. H., Lee, H., Kim, J. A., Shin, H. D., Min, H. J., Seo, D. D., Jang, M. K., Yu, E. and Kim, K. W. 'Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma.' Hepatology 2008 Mar; 47(3): 929-936. Sen, N., Gui, B. and Kumar, R. 'Role of MTA1 in cancer progression and metastasis.' Cancer Metastasis Rev 2014 Dec; 33(4): 879-889. Sherman, M. 'Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.' Cleve Clin J Med 2009 May; 76 Suppl 3: S6-9. Shetly, S. (2002). The role of RNA binding proteins in tumorigenesis, Springer Science+Business Media, LLC Singh, R. R. and Kumar, R. 'MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer.' J Mammary Gland Biol Neoplasia 2007 Sep; 12(2-3): 115-125. Solari, F., Bateman, A. and Ahringer, J. 'The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning.' Development 1999 Jun; 126(11): 2483-2494. Sterner, D. E., Wang, X., Bloom, M. H., Simon, G. M. and Berger, S. L. 'The SANT domain of Ada2 is required for normal acetylation of histones by the yeast SAGA complex.' J Biol Chem 2002 Mar 08; 277(10): 8178-8186. Stevens, C. E., Beasley, R. P., Tsui, J. and Lee, W. C. 'Vertical transmission of hepatitis B antigen in Taiwan.' N Engl J Med 1975 Apr 10; 292(15): 771-774. Stuart, K. E., Anand, A. J. and Jenkins, R. L. 'Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.' Cancer 1996 Jun 1; 77(11): 2217-2222. Su, F. and Schneider, R. J. 'Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins.' J Virol 1996 Jul; 70(7): 4558-4566. Su, I. J., Wang, L. H., Hsieh, W. C., Wu, H. C., Teng, C. F., Tsai, H. W. and Huang, W. 'The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis.' J Biomed Sci 2014 Oct 15; 21: 98. Subramaniam, S., Kelley, R. K. and Venook, A. P. 'A review of hepatocellular carcinoma (HCC) staging systems.' Chin Clin Oncol 2013 Dec; 2(4): 33. Summers, J. 'Three recently described animal virus models for human hepatitis B virus.' Hepatology 1981 Mar-Apr; 1(2): 179-183. Talukder, A. H., Mishra, S. K., Mandal, M., Balasenthil, S., Mehta, S., Sahin, A. A., Barnes, C. J. and Kumar, R. 'MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.' J Biol Chem 2003 Mar 28; 278(13): 11676-11685. Tennant, B. C. 'Animal models of hepadnavirus-associated hepatocellular carcinoma.' Clin Liver Dis 2001 Feb; 5(1): 43-68. Tennant, B. C., Toshkov, I. A., Peek, S. F., Jacob, J. R., Menne, S., Hornbuckle, W. E., Schinazi, R. D., Korba, B. E., Cote, P. J. and Gerin, J. L. 'Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection.' Gastroenterology 2004 Nov; 127(5 Suppl 1): S283-293. Toh, Y. and Nicolson, G. L. 'The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications.' Clin Exp Metastasis 2009 26(3): 215-227. Toh, Y. and Nicolson, G. L. 'Properties and clinical relevance of MTA1 protein in human cancer.' Cancer Metastasis Rev 2014 Dec; 33(4): 891-900. Toh, Y., Pencil, S. D. and Nicolson, G. L. 'A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses.' J Biol Chem 1994 Sep 16; 269(37): 22958-22963. Toh, Y., Pencil, S. D. and Nicolson, G. L. 'Analysis of the complete sequence of the novel metastasis-associated candidate gene, mta1, differentially expressed in mammary adenocarcinoma and breast cancer cell lines.' Gene 1995 Jun 14; 159(1): 97-104. Tokino, T. and Matsubara, K. 'Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma.' J Virol 1991 Dec; 65(12): 6761-6764. Van Assche, E., Van Puyvelde, S., Vanderleyden, J. and Steenackers, H. P. 'RNA-binding proteins involved in post-transcriptional regulation in bacteria.' Front Microbiol 2015 6: 141. Wang, L., Rajan, H., Pitman, J. L., McKeown, M. and Tsai, C. C. 'Histone deacetylase-associating Atrophin proteins are nuclear receptor corepressors.' Genes Dev 2006 Mar 01; 20(5): 525-530. Wu, J. C., Huang, Y. H., Chau, G. Y., Su, C. W., Lai, C. R., Lee, P. C., Huo, T. I., Sheen, I. J., Lee, S. D. and Lui, W. Y. 'Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma.' J Hepatol 2009 Nov; 51(5): 890-897. Wu, L., Tang, Z. Y. and Li, Y. 'Experimental models of hepatocellular carcinoma: developments and evolution.' J Cancer Res Clin Oncol 2009 Aug; 135(8): 969-981. Wurth, L. and Gebauer, F. 'RNA-binding proteins, multifaceted translational regulators in cancer.' Biochim Biophys Acta 2015 Jul; 1849(7): 881-886. Yaginuma, K., Kobayashi, H., Kobayashi, M., Morishima, T., Matsuyama, K. and Koike, K. 'Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children.' J Virol 1987 Jun; 61(6): 1808-1813. Yang, P., Markowitz, G. J. and Wang, X. F. 'The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.' Natl Sci Rev 2014 Jul 14; 1(3): 396-412. Yano, Y., Seo, Y., Azuma, T. and Hayashi, Y. 'Hepatitis B virus and host factors.' Hepatobiliary Surg Nutr 2013 Apr; 2(2): 121-123. Yao, J., Liang, L., Huang, S., Ding, J., Tan, N., Zhao, Y., Yan, M., Ge, C., Zhang, Z., Chen, T., Wan, D., Yao, M., Li, J., Gu, J. and He, X. 'MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma.' Hepatology 2010 Mar; 51(3): 846-856. Yao, Y. L. and Yang, W. M. 'The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.' J Biol Chem 2003 Oct 24; 278(43): 42560-42568. Yoo, Y. G., Kong, G. and Lee, M. O. 'Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.' EMBO J 2006 Mar 22; 25(6): 1231-1241. Yoo, Y. G., Na, T. Y., Seo, H. W., Seong, J. K., Park, C. K., Shin, Y. K. and Lee, M. O. 'Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.' Oncogene 2008 May 29; 27(24): 3405-3413. Yu, L. H., Li, N. and Cheng, S. Q. 'The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma.' Int J Hepatol 2011 2011: 416459. Yu, M. W., Yeh, S. H., Chen, P. J., Liaw, Y. F., Lin, C. L., Liu, C. J., Shih, W. L., Kao, J. H., Chen, D. S. and Chen, C. J. 'Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.' J Natl Cancer Inst 2005 Feb 16; 97(4): 265-272. Yu, S. J. and Kim, Y. J. 'Hepatitis B viral load affects prognosis of hepatocellular carcinoma.' World J Gastroenterol 2014 Sep 14; 20(34): 12039-12044. Zhang, X., You, X., Wang, Q., Zhang, T., Du, Y., Lv, N., Zhang, Z., Zhang, S., Shan, C., Ye, L. and Zhang, X. 'Hepatitis B virus X protein drives multiple cross-talk cascade loops involving NF-kappaB, 5-LOX, OPN and Capn4 to promote cell migration.' PLoS One 2012 7(2): e31458. Zhang, X. Y., DeSalle, L. M., Patel, J. H., Capobianco, A. J., Yu, D., Thomas-Tikhonenko, A. and McMahon, S. B. 'Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein.' Proc Natl Acad Sci U S A 2005 Sep 27; 102(39): 13968-13973. Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S. and Reinberg, D. 'The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.' Cell 1998 Oct 16; 95(2): 279-289. Zhu, R. X., Seto, W. K., Lai, C. L. and Yuen, M. F. 'Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region.' Gut Liver 2016 May 23; 10(3): 332-339. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/67492 | - |
dc.description.abstract | 肝癌 (hepatocellular carcinoma, HCC) 是一高致死率的癌症,主因是發現早期肝癌及有效治療晚期肝癌的方法相當有限。由於肝癌發展的分子機制具有高度異質性,再加上肝癌病人的臨床結果都非常不同,因此,有必要對不同分子特性的肝癌做深入研究,以發展新的診斷治療標記及最適性的個人化醫療。腫瘤轉移抗原1(MTA1)是一個在許多生理及病理現象中都扮演重要角色的分子,它在 B 型肝炎病毒相關肝癌 (HBV-HCC) 過度表現比例遠高其它病原 (etiology) 造成的肝癌,且與肝癌的侵略性及預後不佳高度相關,具有預測肝癌臨床表現及作為診斷治療標的的潛力,但 MTA1 為何在HBV-HCC特別容易過度表現及MTA1參與肝癌發展過程的分子機制還不清楚。在此論文中,我們利用人類肝細胞株、人類臨床檢體及 B 型肝炎相關肝癌的土撥鼠動物模式來探討MTA1在HBV-HCC的分子機制及可能的臨床意義。 第一部分,我們探討土撥鼠動物模式是否適用於研究MTA1在HBV-HCC過度表現及與肝炎病毒X蛋白交互作用的角色。我們透過選殖土撥鼠MTA1 (wk-MTA1) cDNA並且研究其分子功能,以提供我們研究MTA1在土撥鼠動物模式中HBV-HCC作用。wk-MTA1蛋白的序列和組成在不同物種間具高度保留性。在土撥鼠HCC中,wk-MTA1的 mRNA和蛋白質都是過度表現,這個結果與MTA1 在人類HCC中的表達相似。此外,MTA1剪接異構體,wk-MTA1dE4,在土撥鼠HCC中也是過度表達,而且它的表現量約佔總轉錄體(total transcripts)的50%。我們若針對wk-MTA1的表現量進一步分析,結果發現wk-MTA1dE4過度表達的土撥鼠HCC的百分比高於total wk-MTA1過度表達的土撥鼠HCC的百分比(77.8% vs. 61.1%),因此,這個結果顯示在土撥鼠HCC中wk-MTA1dE4可能是比 total wk-MTA1 更敏感的指標。在細胞株的研究中,我們在土撥鼠HCC細胞株(WCH17)中過度表達或敲低 (knockdown) wk-MTA1的表現,結果發現 wk-MTA1可以與土撥鼠肝炎病毒 X 蛋白 (WHx) 相互作用,並且證實wk-MTA1 蛋白在WHx介導的NF-κB活化和增進肝癌細胞移動及侵襲的能力中具有關鍵的作用。 第二部分,我們探討MTA1的相互作用蛋白-類胰島素生長因子II mRNA結合蛋白1(insulin-like growth factor II mRNA-binding protein 1, IGF2BP1)與MTA1 的相互作用在細胞中的角色。IGF2BP1是一種 RNA結合蛋白(RNA binding protein),它被證實會影響致癌基因的mRNA穩定性,並且可以增強腫瘤細胞的遷移能力。我們證實MTA1可以直接與IGF2BP1進行交互作用,而且是RNA-independent的方式。透過 in vivo RNA-immunoprecipitation (RIP),我們發現MTA1和IGF2BP1一樣,都能和IGF2BP1已知的標的基因的mRNA結合在一起。此外,Sequential RIP的實驗顯示MTA1可以與IGF2BP1和MYC mRNA形成ribonucleoprotein (RNP) complex。我們透過建立MTA1 敲低的(MTA1-knockdowned)SK-HEP-1肝癌細胞株,發現當MTA1表現降低時,MYC 無論在mRNA或蛋白質的表現水平上都會降低。我們透過mRNA decay assay,進一步探討MTA1是否會影響 MYC mRNA 的穩定度,我們發現MTA1-knockdowned SK-HEP-1細胞中MYC mRNA的穩定度會下降,因此,MTA1在維持MYC mRNA的穩定度上扮演角色。藉由 in vitro RNA-pull down,我們確認了MTA1具有直接結合RNA的能力。在人類肝癌組織中,MTA1與MYC的mRNA表現量之間呈現正相關。 第三部分,我們利用回溯性的資料分析,探討MTA1在HBV-HCC患者手術治療後的腫瘤復發的臨床意義。此研究共納入了102例接受肝腫瘤切除術的HBV-HCC患者。我們發現人類MTA1dE4過度表達HCC的百分比高於總MTA1過度表達的HCC的百分比(49% vs. 20.6%),這個結果與土撥鼠HCC的發現相似。在平均追蹤的48.2個月中,有67 位(65.7%)HBV-HCC患者腫瘤復發,其中有25位是早期腫瘤復發(early recurrence; 復發時間小於等於一年)和42位是晚期腫瘤復發(late recurrence; 復發時間大於一年)。此外,我們發現MTA1dE4過度表達的HBV-HCC患者具有較高的腫瘤復發率(tumor recurrence rate),尤其是早期復發。根據Stepwise multiple COX proportional hazards regression analysis的分析結果,當HBV-HCC患者具有腫瘤直徑大於3 公分[風險比(Hazards ratio, HR):10.165; 95% 信賴區間 (confidence interval, CI): 1.366-5.665; P = 0.024] 和血清中甲型胎兒蛋白(alpha fetal protein, AFP)水平 ≥ 200ng/ mL [HR: 4.028; 95% CI: 1.618-10.03; P = 0.03] 有較高的早期腫瘤復發的風險,顯示腫瘤直徑大於3公分和高血清甲型胎兒蛋白是早期復發的獨立預測因子。透過分層分析(stratified analysis),把肝硬化(liver cirrhosis)的效應列入考慮後,在肝硬化患者中腫瘤直徑大於3公分和早期復發風險之間有強烈關聯 [HR:10.629; 95% CI: 1.425-79.31; P = 0.021]。然而,高血清甲型胎兒蛋白和HBV-HCC中過度表達MTA1dE4則是呈現邊緣性顯著(borderline significance) (P = 0.059和P = 0.083)。 綜合上述三部分的研究,我們的研究結果支持了土撥鼠HCC是適合探討MTA1在HBV-HCC分子特徵的動物模式。此外,我們的研究探討MTA1在 HBV-HCC的分子機制和臨床意義,為 MTA1及其剪接異構體 MTA1dE4 的重要性提供了線索。我們首次揭露MTA1以前從未被報導過的結合RNA的新功能,並且發現MTA1在細胞質的潛在功能及穩定致癌基因mRNA的新致癌機制。因此,本論文的研究成果我們認為有助於未來闡明MTA1在HBV-HCC的分子機制和臨床意義,及優化MTA1過度表達的HBV-HCC的治療策略並發展最適性的個人化醫療奠定重要基礎。 | zh_TW |
dc.description.abstract | Lack of sensitive biomarkers for timely diagnosis and the absence of effective therapeutics for treatment are the two major reasons for poor outcome in patients with advanced hepatocellular carcinoma (HCC). The molecular mechanism underlying HCC is highly heterogeneous and the clinical outcome of HCC is very variable among patients. Hence, it is necessary to study the molecular mechanisms for different etiologies of HCC to develop specific new markers for diagnosis and therapy. Metastatic tumor antigen 1 (MTA1) is a multifaceted master coregulator that plays critical roles in the physiological and pathological processes. MTA1 overexpression is more frequent in HBV-related HCC (HBV-HCC) than in HCC of other etiologies. Furthermore, it is highly associated with the invasiveness and poor prognosis of HCC. However, the underlying mechanisms for the higher percentage of MTA1 overexpression in HBV-HCC and the roles of MTA1 in HBV-associated hepatocarcinogenesis remain elusive. The aim of this dissertation is to investigate the molecular functions and clinical implications of MTA1 in HBV-HCC by use of human liver cell lines, clinical samples and woodchuck HCC model. In the first part of this study, we examined the appropriateness of using the woodchuck model for studying the roles of MTA1 in HBV-HCC with respect to MTA1 overexpression and molecular interaction with the hepadnavirus X protein. To investigate the roles of MTA1 in HBV-associated hepatocarcinogenesis in the woodchuck model, we cloned the woodchuck MTA1 (wk-MTA1) complementary (c)DNA and characterized its molecular functions. The sequence and organization of the wk-MTA1 protein were highly conserved among different species. Similar to its expression in human HCC, wk-MTA1 was upregulated in woodchuck HCC, as determined at RNA and protein levels. Furthermore, an MTA1-spliced variant, wk-MTA1dE4, was overexpressed in woodchuck HCC, and it was attributed to approximately 50% of the total transcripts. The percentage of wk-MTA1dE4-overexpressed woodchuck HCCs was higher than that of the total wk-MTA1-overexpressed HCCs (77.8% vs. 61.1%) and wk-MTA1dE4 may represent a more sensitive marker than the total wk-MTA1 in woodchuck HCC. We overexpressed or knocked down wk-MTA1 in a woodchuck HCC cell line and demonstrated that wk-MTA1 could interact with the WHV X protein (WHx) and play indispensable roles in WHx-mediated NF-κB activation and tumor cell migration- and invasion-promoting activities. In the second part of this study, we examined the roles of MTA1-interacting protein, IGF2BP1 (insulin-like growth factor II mRNA-binding protein 1) in MTA1-mediated functions in vitro. IGF2BP1 is an oncofetal RNA-binding protein (RBP) and has been shown to influence the mRNA stability of several oncogenes and can enhance the migration ability of tumor cells. We found that MTA1 could directly interact with IGF2BP1 in an RNA-independent manner. By in vivo RNA-immunoprecipitation (RIP) assay, we found that MTA1 could associate with the known IGF2BP1 target mRNAs. In addition, using sequential RIP, we demonstrated that MTA1 could form a ribonucleoprotein complex with IGF2BP1 and MYC mRNA. Using knockdown experiments, we showed that both mRNA and protein expression levels of MYC in MTA1-konckdowned SK-HEP-1 cells were decreased. Furthermore, by use of mRNA decay assay, we found that the half-life of MYC mRNA in MTA1-konckdowned SK-HEP-1 cells was decreased. By in vitro RNA-pull down, we confirmed that MTA1 exhibites direct RNA-binding ability. A positive correlation between MTA1 and MYC mRNA expression levels in human clinical HCC samples could be illustrated. These results suggested that MTA1 plays an integral role in stabilizing mRNA of MYC. This study reveals the novel RNA-binding function of MTA1 and provides important information to the molecular mechanism of MTA1 in cytoplasm and oncogenesis. In the third part of this study, we characterized the clinical significance of MTA1 overexpression in postoperative recurrence of HBV-HCC. In this retrospective cohort study, a total of 102 patients with HBV-HCCs underwent hepatic resection were enrolled. We found that the percentage of human MTA1dE4-overexpressed HCCs was higher than that of the total MTA1-overexpressed HCCs (49% vs. 20.6%), which was similar to those findings in woodchuck HCCs. During a mean follow-up period of 48.2 months, patients with MTA1dE4-overexpressed HCCs had a significantly higher rate of tumor recurrence, especially in early recurrence. Stepwise multiple COX proportional hazards regression analysis showed that large tumor size (over 3-cm in diameter) [hazard ratio (HR), 10.165; 95% confidence interval (CI), 1.366-5.665; P= 0.024] and high serum AFP level (≧ 200 ng/mL) [HR, 4.028; 95% CI, 1.618-10.03; P= 0.03] were associated with early tumor recurrence in HBV-HCC patients. Stratified analysis showed that larger tumor size was still associated with early recurrence in cirrhotic patients (HR, 10.629; 95% CI, 1.425-79.31; P= 0.021), whereas high serum AFP level and high MTA1dE4 expression were associated with borderline significance (P= 0.059 and 0.083). In summary, our results support the hypothesis that woodchuck HCC recapitulates HBV-HCC with respect to the molecular characteristics of MTA1 and provides new clues for conducting mechanistic studies of MTA1 in HBV-associated hepatocarcinogenesis, including the possible clinical significance of MTA1dE4. Our study also reveals the novel RNA-binding function of MTA1 and potentially provides a paradigm for a broader understanding of the molecular function of MTA1 in the cytoplasm and oncogenic activities. Therefore, results of this dissertation lay the groundwork for elucidating the detailed molecular mechanisms and clinical implications of MTA1 and optimizing therapeutic strategy to treat MTA1-overexpressed HBV-HCC in the era of personalized medicine. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T01:34:35Z (GMT). No. of bitstreams: 1 ntu-106-D99421001-1.pdf: 12113806 bytes, checksum: a9fa579d76a2c7b36d5a19a3a151fc47 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員審定書 ....................................................................................................................i 誌謝.............................................................................................................................................ii List of Figures..................................................................................................................ix List of Tables...................................................................................................................xii 中文摘要..........................................................................................................................xiv Abstract.........................................................................................................................xviii Chapter 1 Introduction....................................................................................................1 1.1 Background of Dissertation 1 1.2 Literature Review 4 1.2.1 Hepatitis B Virus-related Hepatocellular Carcinoma (HBV-HCC)...........4 1.2.1.1 Global trends in the etiology and incidence of hepatocellular carcinoma................................................................................................4 1.2.1.2 Current trends and practice in diagnosis and treatment of HCC.............5 1.2.1.3 Health burden of HBV-related HCC in Taiwan......................................8 1.2.1.4 Role of HBV in the pathogenesis of HCC...............................................9 1.2.1.5 Animal models for studying HBV-related HCC....................................12 1.2.2 Metastatic Tumor Antigen 1 (MTA1)...........................................................14 1.2.2.1 Introduction for MTA1-the structural domains, the splice variants, and the subcellular localization of MTA1 protein........................................15 1.2.2.2 Properties of MTA1 protein: biological, clinical and therapeutic relevance................................................................................................19 1.2.3 Relationship between the HBV and MTA1 in HCC .................................24 1.3 Research Questions and Niches 26 1.4 Hypothesis and Specific Aims 29 Chapter 2 Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model................................................33 2.1 Introduction 34 2.2 Materials and Methods 38 2.3 Results 47 2.3.1 Cloning and sequence analysis of woodchuck MTA1 cDNA ...........................47 2.3.2 Wk-MTA1 and its splice variants are overexpressed in WHV-infected woodchuck HCC tissues ..........................................................................................48 2.3.3 Wk-MTA1 is induced by WHx and plays an essential role in WHx-mediated wk-NF-κB activation ...............................................................................................50 2.3.4 Wk-MTA1 enhances tumor cell motility and invasiveness ..............................52 2.4 Discussion 53 Chapter 3 A novel function of metastatic tumor antigen 1 in the modulation of RNA stability of oncogenes in hepatoma cells .......................................................61 3.1 Introduction 62 3.2 Material and Methods 65 3.3 Results 77 3.3.1 MTA1 could interact with an oncofetal RNA-binding protein IGF2BP1..........77 3.3.2 MTA1 could form RNP complexes with IGF2BP1 ..........................................78 3.3.3 MTA1 could enhance MYC mRNA stability ....................................................79 3.3.4 MTA1 is a novel MYC mRNA binding protein ................................................81 3.3.5 N-terminus of MTA1 protein is responsible for RNA-binding ability .............82 3.3.6 MTA1 knockdown inhibits cell proliferation of hepatoma cell ........................83 3.4 Discussion 85 Chapter 4 A metastasis tumor antigen 1 splicing variant, MTA1dE4, correlates with early tumor recurrence after surgical resection of hepatitis B virus-related hepatocellular carcinoma................................................................................93 4.1 Introduction 94 4.2 Material and Methods 96 4.3 Results ......101 4.3.1 Baseline characteristics of enrolled patients....................................................101 4.3.2 MTA1 and its splice variant, MTA1dE4, are overexpressed in HBV-HCC....101 4.3.3 Correlation between MTA1 expression and clinicopathological features.......103 4.3.4 Cumulative tumor recurrence rates .................................................................104 4.3.5 Factors predisposing tumor recurrence after surgical resection in HBV-HCC patients .....................................................................................................................105 4.4 Discussion 107 Chapter 5 Dissertation Discussion..............................................................................114 Chapter 6 Perspectives................................................................................................118 6.1 Applications of the Study 118 6.2 Recommendations for Future Research 119 6.2.1 Interplay between MTA1 and HBV..................................................................119 6.2.2 Optimization of using the woodchuck HCC model for exploring the role of MTA1 in HBV-related hepatocarcinogenesis ....................................................120 6.2.3 Role of MTA1 in drug resistance of HCC .......................................................121 6.2.4 Possible functional difference between the full-length MTA1 and MTA1dE4...........................................................................................................122 6.2.5 Exploration of the possibility of MTA1 as a potential tumor antigen.............123 6.2.6 The underlying mechanism of MTA1 in protecting RNAs from degradation .......................................................................................................124 6.2.7 Exploration of the potential mechanism(s) of MTA1 in HBV-related hepatocarcinogenesis..........................................................................................125 References.....................................................................................................................126 Figures...........................................................................................................................140 Tables.............................................................................................................................179 Abbreviations................................................................................................................193 | |
dc.language.iso | en | |
dc.title | 腫瘤轉移抗原1在 B 型肝炎病毒相關肝細胞癌的角色 | zh_TW |
dc.title | Roles of Metastatic Tumor Antigen 1 in Hepatitis B Virus-related Hepatocellular Carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 吳慧琳 | |
dc.contributor.oralexamcommittee | 謝嘉玲,陶秘華,周祖述,王弘毅,鄭永銘 | |
dc.subject.keyword | 肝細胞癌,腫瘤轉移抗原1,B型肝炎病毒,土撥鼠,剪接異構體,RNA穩定度, | zh_TW |
dc.subject.keyword | hepatocellular carcinoma,metastatic tumor antigen 1,hepatitis B virus,woodchuck,splicing variant,RNA stability, | en |
dc.relation.page | 195 | |
dc.identifier.doi | 10.6342/NTU201702230 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
Appears in Collections: | 臨床醫學研究所 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
ntu-106-1.pdf Restricted Access | 11.83 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.